Member Directory

Kurome Therapeutics is a preclinical stage company that is developing effective cancer therapies designed to work where others fail by circumventing the cancer cell’s ability to evade therapy. Currently focused on improving health in poor prognosis acute myeloid leukemia (AML) patients, Kurome’s targeted approach also has the potential to work across a range of hematopoietic cancers including pre-leukemic conditions, such as myelodysplastic syndromes (MDS). With parallel development of a companion diagnostic to aid in identification of patient populations most likely to benefit from the approach of targeting adaptive resistance mechanisms, these therapies have the potential to also be extended to the treatment of solid tumors. Specifically, Kurome Therapeutics is developing a series of IRAK1/4, panFLT3 inhibitors that have been demonstrated in preclinical studies to: increase overall survival in cell line and patient-derived xenograft models, well beyond that of existing FLT3 inhibitors; synergize with Venclexta (Venetoclax) to improve Venclexta potency; maintain complete efficacy even in settings of adaptive resistance to FLT3 inhibitors; identified a biomarker that correlates with poor prognosis in AML patients and maximal activation of immune signaling through this pathway in AML cells.